secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001558370-25-000823
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio signs AbbVie deal: $52M upfront, up to $2.1B milestones for masked T-cell engagers
--------------------------------------------------------------------------------

- Upfront $52M ($42M cash + $10M equity at $2.30/shr); AbbVie gets options for 4 masked TCE programs and license for masked antibody.
- Contingent payments up to ~$2.1B in option fees and milestones plus tiered mid-to-high single-digit royalties.
- Xilio announces three wholly-owned preclinical masked TCE programs targeting PSMA, CLDN18.2, STEAP1 with candidate nomination timelines through 2027.
- Cash runway extended into Q1 2026 with upfront payments; additional milestones require further capital.
- Collaboration validates Xilio's tumor-activation platform; CEO highlights potential to improve TCE tolerability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025000823/0001558370-25-000823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025000823/xlo-20250210x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer